These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 30246640)

  • 1. Improved In vivo Effect of Chrysin as an Absorption Enhancer Via the Preparation of Ternary Solid Dispersion with Brij®L4 and Aminoclay.
    Lee SH; Lee YS; Song JG; Han HK
    Curr Drug Deliv; 2019; 16(1):86-92. PubMed ID: 30246640
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Flavonoids chrysin and benzoflavone, potent breast cancer resistance protein inhibitors, have no significant effect on topotecan pharmacokinetics in rats or mdr1a/1b (-/-) mice.
    Zhang S; Wang X; Sagawa K; Morris ME
    Drug Metab Dispos; 2005 Mar; 33(3):341-8. PubMed ID: 15608138
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhanced dissolution and bioavailability of biochanin A via the preparation of solid dispersion: in vitro and in vivo evaluation.
    Han HK; Lee BJ; Lee HK
    Int J Pharm; 2011 Aug; 415(1-2):89-94. PubMed ID: 21645596
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of a Ternary Solid Dispersion Formulation of LW6 to Improve the In Vivo Activity as a BCRP Inhibitor: Preparation and In Vitro/In Vivo Characterization.
    Bajracharya R; Lee SH; Song JG; Kim M; Lee K; Han HK
    Pharmaceutics; 2019 May; 11(5):. PubMed ID: 31052438
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modulation of Intestinal Transport and Absorption of Topotecan, a BCRP Substrate, by Various Pharmaceutical Excipients and Their Inhibitory Mechanisms of BCRP Transporter.
    Sawangrat K; Yamashita S; Tanaka A; Morishita M; Kusamori K; Katsumi H; Sakane T; Yamamoto A
    J Pharm Sci; 2019 Mar; 108(3):1315-1325. PubMed ID: 30389568
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exploration of supersaturable lacidipine ternary amorphous solid dispersion for enhanced dissolution and in vivo absorption.
    Guan J; Jin L; Liu Q; Xu H; Wu H; Zhang X; Mao S
    Eur J Pharm Sci; 2019 Nov; 139():105043. PubMed ID: 31415903
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preparation, characterization and in vitro/vivo evaluation of tectorigenin solid dispersion with improved dissolution and bioavailability.
    Shuai S; Yue S; Huang Q; Wang W; Yang J; Lan K; Ye L
    Eur J Drug Metab Pharmacokinet; 2016 Aug; 41(4):413-22. PubMed ID: 25669445
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improvement of the oral drug absorption of topotecan through the inhibition of intestinal xenobiotic efflux transporter, breast cancer resistance protein, by excipients.
    Yamagata T; Kusuhara H; Morishita M; Takayama K; Benameur H; Sugiyama Y
    Drug Metab Dispos; 2007 Jul; 35(7):1142-8. PubMed ID: 17446265
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Amorphous Solid Dispersion of Chrysin in Plasdone
    Wang C; Liu X; Zhao R; Yang M; Liu W; Dai Q; Bao X; Chen Y; Ma J
    Pharmaceutics; 2023 Sep; 15(10):. PubMed ID: 37896138
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improved pH-independent dissolution and oral absorption of valsartan via the preparation of solid dispersion.
    Park YJ; Lee HK; Im YB; Lee W; Han HK
    Arch Pharm Res; 2010 Aug; 33(8):1235-40. PubMed ID: 20803127
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Elevated system exposures of baicalin after combinatory oral administration of rhein and baicalin: Mainly related to breast cancer resistance protein (ABCG2), not UDP-glucuronosyltransferases.
    Zhang Y; Zhang M; Hu G; Zhang Z; Song R
    J Ethnopharmacol; 2020 Mar; 250():112528. PubMed ID: 31884038
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan.
    Jonker JW; Smit JW; Brinkhuis RF; Maliepaard M; Beijnen JH; Schellens JH; Schinkel AH
    J Natl Cancer Inst; 2000 Oct; 92(20):1651-6. PubMed ID: 11036110
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential effects of chrysin on nitrofurantoin pharmacokinetics mediated by intestinal breast cancer resistance protein in rats and mice.
    Kawase A; Matsumoto Y; Hadano M; Ishii Y; Iwaki M
    J Pharm Pharm Sci; 2009; 12(2):150-63. PubMed ID: 19732493
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improved pH-dependent drug release and oral exposure of telmisartan, a poorly soluble drug through the formation of drug-aminoclay complex.
    Yang L; Shao Y; Han HK
    Int J Pharm; 2014 Aug; 471(1-2):258-63. PubMed ID: 24834880
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhancement of dissolution and oral bioavailability by adjusting microenvironment pH in crocetin ternary solid dispersions: Optimization, characterization, in vitro evaluation, and pharmacokinetics.
    Tong Z; Liu X; Tao Y; Feng P; Luan F; Jie X; Xie Z; Pu F; Xu Z; Wang P
    Drug Deliv Transl Res; 2024 Jul; 14(7):1923-1939. PubMed ID: 38117406
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Using novobiocin as a specific inhibitor of breast cancer resistant protein to assess the role of transporter in the absorption and disposition of topotecan.
    Su Y; Hu P; Lee SH; Sinko PJ
    J Pharm Pharm Sci; 2007; 10(4):519-36. PubMed ID: 18261372
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fabrication and evaluation of pH-modulated solid dispersion for telmisartan by spray-drying technique.
    Marasini N; Tran TH; Poudel BK; Cho HJ; Choi YK; Chi SC; Choi HG; Yong CS; Kim JO
    Int J Pharm; 2013 Jan; 441(1-2):424-32. PubMed ID: 23174408
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exploring the Potential of Mesoporous Silica as a Carrier for Puerarin: Characterization, Physical Stability, and In Vivo Pharmacokinetics.
    Wang Z; Ye BN; Zhang YT; Xie JX; Li WS; Zhang HT; Liu Y; Feng NP
    AAPS PharmSciTech; 2019 Aug; 20(7):289. PubMed ID: 31414349
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel composition of ticagrelor by solid dispersion technique for increasing solubility and intestinal permeability.
    Kim SJ; Lee HK; Na YG; Bang KH; Lee HJ; Wang M; Huh HW; Cho CW
    Int J Pharm; 2019 Jan; 555():11-18. PubMed ID: 30448313
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of the flavonoid chrysin on nitrofurantoin pharmacokinetics in rats: potential involvement of ABCG2.
    Wang X; Morris ME
    Drug Metab Dispos; 2007 Feb; 35(2):268-74. PubMed ID: 17093006
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.